Postdoctoral Fellow- Cell Therapy/Hematopoietic Cell Transplantation
immunology, immunotherapy, transplantation
The Center for Cancer Research (CCR) is working to solve the most pressing problems in the field through basic, translational and clinical cancer research to create the cancer medicines of tomorrow and is dedicated to preparing the next generation of cancer researchers. Read more about CCR, the benefits of working at CCR and hear from our staff on their CCR experiences.
Dr. Christopher Kanakry, Lasker Clinical Research Scholar/tenure-track investigator in the Experimental Transplantation and Immunology Branch in Bethesda, Maryland, is recruiting a Postdoctoral Research Fellow in tumor immunology to study the integration of antigen-specific cellular therapy and hematopoietic cell transplantation.
The Kanakry Laboratory utilizes cellular and molecular immunologic tools to address mechanistic and translational questions with direct relevance for improving outcomes of patients undergoing HCT. The laboratory is within the broader NCI community, which provides a vibrant and enriching environment for research in immunology, immunotherapy, transplantation, and cancer with ready access to numerous cutting-edge technologies.
Candidates should have a PhD and/or MD degree. Substantial experience in T-cell engineering, mouse modeling, and flow cytometry is highly encouraged.
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative therapy for otherwise incurable hematologic malignancies. The use of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis recently has revolutionized the HCT field by making HCT available to nearly all patients and effectively preventing both severe acute and chronic GVHD. This approach also minimizes the post-transplant immunosuppressive burden, making this a promising platform for the integration of other immunotherapeutic strategies to prevent malignancy relapse. However, the mechanisms underlying PTCy’s clinical efficacy have been poorly understood. Recent work performed in the laboratory of Dr. Christopher Kanakry (e.g., https://www.jci.org/articles/view/124218) has disproven the existing paradigm of understanding, and we are actively developing a comprehensive new model of understanding. Simultaneously, we are using these new biologic understandings to ra tionally improve transplantation approaches, including developing new strategies to prevent or treat malignancy relapse, which currently is the leading reason for failure of HCT.
Send a statement of interest and curriculum vitae to Dr. Christopher Kanakry, M.D. at email@example.com.
HHS, NIH, and NCI are Equal Opportunity Employers